FindTrial
Sign In

Usefulness of Beta-D Glucan (BDG) test in the treatment of fungal diseases in intensive care setup

Utility of (1â??3)-β-D Glucan (BDG) in the management of invasive fungal diseases in critical care unit - NILL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055921
Enrollment
330
Registered
2023-07-31
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B49- Unspecified mycosis

Interventions

Intervention1: Nil: Nil

Sponsors

Apollo Hospitals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Above 18 years of age who are admitted in critical acre unit for whom BDG test ahs been ordered

Exclusion criteria

Exclusion criteria: No specific exclusion criteria

Design outcomes

Primary

MeasureTime frame
Assess the impact of BDG in therapeutic decision makingTimepoint: 1 year—

Secondary

MeasureTime frame
1.To know the indication for ordering BDG assay.â?¯â?¯â?¯ Timepoint: 1 year;2. To enumerate the host factors for acquiring IFD.â?¯Timepoint: 1 year—

Countries

India

Contacts

Public ContactSri Showmiya G

Apollo hospital, Off Greams road, chennai

ashwin.mani@gmail.com6380915692

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026